Evidence map›Paper›PMID 41660098›Full record

SynthesisPeerJ2026

Cardioprotective effect of resveratrol in myocardial ischemia/reperfusion injury and myocardial infarction: a pre-clinical meta-analysis in animal studies.

Shi-Jie Wei, Qi-Hao Guo, Xin-Yu Wei, Si-Yu Chen, Sheng Deng, Liang An, Wen-Jing Zeng, Yi-Fan Zeng

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shi-Jie Wei *Department of Cardiovascular Surgery, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Qi-Hao Guo *Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xin-Yu WeiDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Si-Yu ChenDepartment of Pharmacy, Shengjing Hospital of China Medical University, China Medical University, Shenyang, China.
Sheng DengDepartment of Pharmacy, Shengjing Hospital of China Medical University, China Medical University, Shenyang, China.
Liang AnThe Fourth Hospital of Baotou, Baotou, Neimenggu, China.
Wen-Jing ZengDepartment of Pharmacy, Shengjing Hospital of China Medical University, China Medical University, Shenyang, China.
Yi-Fan ZengDepartment of Cardiovascular Surgery, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This meta-analysis aimed to assess the cardioprotective effect of resveratrol (RES) against myocardial ischemia/reperfusion injury (MIRI) and myocardial infarction (MI) in the animal. PubMed, Web of Science, and EMBASE were searched. Primary outcomes included myocardial infarct size (IS) and cardiac function. Secondary outcomes included cardiac injury enzyme, oxidative stress level, inflammatory cytokine, and apoptosis rate. Subgroup analysis, publication bias, sensitivity analysis, meta-regression, and dosage-efficacy analysis were used to evaluate the risk of bias. Fifty-seven studies were included involving 1,125 animals. The results showed that RES treatment decreased IS in animal models of MIRI (SMD: -5.44; 95% CI [-6.42 to -4.45];

Indexed as

Cardiotonic AgentsMyocardial InfarctionMyocardial Reperfusion InjuryResveratrolStilbenesAnimalsApoptosisCytokinesDisease Models, AnimalOxidative StressCardiotonic AgentsCytokinesResveratrolStilbenesMeta-analysisMyocardial infarctionMyocardial ischemia/reperfusionPre-clinical evidenceResveratrol

Identifiers

PMID41660098
PMCPMC12882730

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.